The Epidemiology of Stargardt Disease in the United Kingdom


Published in:
Ophthalmology Retina

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2017 The Authors and the American Academy of Ophthalmology.
This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
The Epidemiology of Stargardt Disease in the United Kingdom

Kurt Spiteri Cornish, FRCOphth,1 Jason Ho, FRCOphth,2,3 Susan Downes, FRCOphth,4 Neil W. Scott, PhD,5 James Bainbridge, PhD,2,3 Noemi Lois, MD, PhD6

**Purpose:** To establish the incidence of Stargardt disease (STGD) in the United Kingdom and define baseline characteristics of newly diagnosed patients.

**Design:** Prospective epidemiologic study undertaken under the auspices of the British Ophthalmological Surveillance Unit (BOSU).

**Participants:** New incident cases of STGD in the United Kingdom reported by ophthalmologists to BOSU during a 12-month period, from June 1, 2012, to June 1, 2013.

**Methods:** Once a new case of STGD was reported, an incident questionnaire was sent to the reporting ophthalmologist, followed by a follow-up questionnaire (when required) 6 months later.

**Main Outcome Measures:** Patient demographics, baseline characteristics including visual acuity, and findings on slit-lamp biomicroscopy, as well as diagnostic technologies undertaken at baseline and their findings, including electrophysiology, fundus autofluorescence, fluorescein angiography, and genetic testing.

**Results:** A total of 81 new cases of STGD were reported during the 12-month period of the study; baseline data were obtained on 70 (86%) of these. These results suggest an annual incidence in the United Kingdom of STGD estimated herein appears to be lower than that repeatedly quoted in the literature. Fundus autofluorescence and electrophysiology testing are most commonly used for the evaluation of patients with STGD. Ophthalmology Retina 2017;1:1–6 © 2017 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

**Conclusions:** Even considering possible limitations related to incomplete ascertainment, this is the first prospective epidemiology study that provides indication of the incidence of STGD in the United Kingdom. The incidence of STGD estimated herein appears to be lower than that repeatedly quoted in the literature. Fundus autofluorescence and electrophysiology testing are most commonly used for the evaluation of patients with STGD.

Stargardt disease (STGD) and fundus flavimaculatus (FFM) are synonymous terms used to refer to the same recessively inherited macular dystrophy that affects photoreceptor (PR) and retinal pigment epithelium (RPE).1,2 The condition was first recognized in 1909 by Stargardt, who described 7 patients with a recessively inherited macular dystrophy characterized by macular atrophy surrounded by deep yellow-white retinal lesions.1 Other features of the disease include initial loss of vision without clinical signs on funduscopy.1 The term FFM was later coined by Franceschetti, who described a disease characterized by the presence of “fishlike” (pisciform) deep yellow-white retinal lesions, now referred to as “flecks.”2 Since the original description, there have been numerous studies evaluating different aspects of this inherited retinal disorder.

The incidence of STGD was estimated to be between 1 in 8000 and 1 in 10 000 in the United States.3 The 1 in 10 000 incidence has been repeatedly quoted in the literature.3–5 This estimate, however, does not derive from an epidemiology study but rather from Blacharski’s observation that STGD is more common than retinoblastoma (the incidence of which Blacharski estimated to be 1 in 15 000) but less common than retinitis pigmentosa (which Blacharski estimated to occur in 1 in 5000 individuals). As new therapies for STGD are currently being investigated, including embryonic stem cell–derived retinal pigment epithelial cell transplantation6 and ABCA4 gene replacement therapy using the StarGen,7 elucidating the incidence and baseline characteristics of patients presenting with this macular dystrophy would be invaluable to plan future therapeutic strategies. This was thus the purpose of the study presented herein. In order to accomplish this purpose, we undertook a prospective population-based epidemiologic study to determine the incidence of STGD in the United Kingdom and gain knowledge on the baseline characteristics of patients presenting with this retinal disorder.

**Methods**

The study was conducted in accordance with the tenets of the Declaration of Helsinki. Ethical approval was sought and obtained from the North of Scotland National Research Ethics Service and the NHS Grampian Research and Development Committees before the initiation of the study.

Patients with newly diagnosed STGD (new incident cases) were identified prospectively through active surveillance by the British...
Ophthalmological Surveillance Unit (BOSU) during a 12-month period from July 2012 to June 2013, both inclusive. This surveillance scheme involves all ophthalmologists in the United Kingdom (consultants and associate specialists). Before the study was initiated, the BOSU informed ophthalmologists about the new ocular conditions under investigation (STGD), including the case definition. For the purpose of the study, STGD was defined as a recessively inherited retinal dystrophy presenting at any age with a number of characteristics, which include macular changes (mottling, bull’s-eye appearance, and/or atrophy) and/or retinal flecks (active or resorbed) with relative peripapillary sparing. An active fleck is defined as an accumulation of yellow material at the level of the RPE, which appears as an area of hypofluorescence on fundus fluorescein angiography (FFA) and as an area of increased signal on autofluorescence (AF) imaging. A resorbed fleck is defined as a small focus of depigmentation or atrophy in the RPE, appearing as an area of hyperfluorescence on FFA and reduced AF signal.

Genetic confirmation (i.e., presence of disease-causing variations in both alleles of the ABCA4) was not required for the diagnosis of the cases reported. The diagnosis was made by findings on clinical examination (as per the above description) and ancillary studies including pattern and full-field electroretinography (PERG and PFERG, respectively), fluorescein angiography, and fundus AF. A flat or very reduced PERG (with or without PFERG abnormalities), dark choroid on FFA, and multiple focal or reduced or increased signal on fundus AF imaging with relative peripapillary sparing would be suggestive of the diagnosis. Consultation with national experts on inherited retinal diseases was sought. Ophthalmologists were specifically questioned in the incident questionnaire as to whether further testing was planned for the patient, a further follow-up questionnaire was sent 6 months after receipt of the incident questionnaire. For this study, units that had not reported cases but that were covering a population sufficiently large to have been expected to have evaluated a case of STGD were independently contacted to confirm the absence of incident STGD cases during the 12-month study period.

Before the initiation of the study, retinal specialists from all over the UK, who were thought to form largely the group that would be most likely reporting new incident cases, were approached and informed about the upcoming study and asked to provide feedback on the study card (case definition) and questionnaires developed for the study. Their input was incorporated in the final materials for the study.

The incident questionnaire collected data on age of onset, gender, ethnicity, family history, and symptoms at presentation. Baseline examination findings including best-corrected visual acuity and fundus features and results of ancillary studies including electrophysiology, AF, FFA, and genetic testing, if available, were also sought. Ophthalmologists were specifically questioned in the incident questionnaire as to whether further testing was planned in the reported case and, if so, follow-up questionnaires were sent at 6 months to collect the results of these tests. To avoid possible reporting duplications related to the fact that patients could be diagnosed in one center and referred to a tertiary center specializing in the diagnosis and evaluation of patients with inherited retinal disorders, nonidentifiable details (date of birth and first part of postcode) were collected from each patient in the incident questionnaire. In the event that a patient was referred to a different hospital, the 2 separate questionnaires would have the same patient details and would be counted as 1 single patient, if this was confirmed to be the case. Reporting ophthalmologists were encouraged to contact KSC or NL in case of doubt about the possible diagnosis of STGD; in some instances, anonymized images and other investigations were, thus, provided to and analyzed by 2 of the authors (KSC and NL) to confirm or exclude the diagnosis of STGD.

**Results**

**New Incident Cases Reported**

From July 2012 to June 2013 (both months inclusive), a total of 86 cards were returned to BOSU reporting new incident cases. Of these, 5 cases were excluded: 2 because although they were initially thought to be STGD, they were later diagnosed as cone dystrophy and pattern dystrophy by the reporting ophthalmologist; and 3 because they had been diagnosed outside the specified study period. Thus, there were 81 incident cases; baseline data were obtained through the incident questionnaire in 70 of 81 new incident cases (86%), and follow-up data were obtained in 6 of 7 (85.7%) of the 6-month questionnaires sent. During the study period, there were a total of 1251 reporting ophthalmologists for all BOSU studies and the overall card return rate was 74.5%.

**Incidence of Stargardt Disease in the United Kingdom**

In 2012, the UK Office for National Statistics projected the population to be 63 700 000. Considering all 81 cases reported to BOSU, the estimated incidence of STGD in the UK would be 0.127 per 100 000 per year (95% confidence interval, 0.099–0.155). If only the 70 cases of STGD for which data were available to the researchers (questionnaires returned) and the diagnosis of STGD confirmed were to be included, then the estimated annual incidence of STGD in the UK would be 0.110 per 100 000 (95% confidence interval, 0.084–0.136) of the general population per year. Therefore these results would suggest an annual incidence of STGD-FFM in the UK of between 0.110 and 0.127 per 100 000 individuals per year.

**Patient Demographics**

The majority of reported cases of STGD affected young adults, with a median age of 27 years (mean 27.4 years; range 5–64 years). The majority were white British (77%), with a higher proportion of female subjects affected (61.4%). A summary of the baseline characteristics of incident cases is presented in Tables 1 to 3.

**Symptoms**

The vast majority of cases were symptomatic (90.0%), with reduced vision being the most common symptom (80.0%), followed by nyctalopia (12.9%) and photophobia (11.4%).

**Visual Acuity**

Visual acuity at presentation was recorded in either Snellen or logarithm of the minimum angle of resolution (logMAR). For the purpose of this study, Snellen visual acuity values were converted into logMAR acuities using standard conversion tables. Visual
50 patients, macula and/or midperipheral retina of 1 or both eyes. In 7 of these cases the key features of the disease was the presence of active or resorbed flecks. AF imaging was obtained in 32 of 70 patients. In 21 patients (65.6%), active retinal flecks were present, as identified clinically (n = 36), on AF imaging (n = 2), or both. The second most common clinical finding at the macula was atrophy, which was detected in over one-third (n = 26, 37.1%) of patients. Macular pigment mottling and bull’s-eye maculopathy were present in approximately one-quarter of cases (28.6% and 24.3%, respectively). There were no fundus abnormalities in the midperipheral and peripheral retina in 52 cases (74.3%). The most common sign in the retinal midperiphery was active flecks, present in 12 (17.1%) patients.

Clinical Features on Slit-Lamp Biomicroscopy

The diagnosis of STGD was based on the specific case definition that was published by BOSU for the duration of the study. One of the key features of the disease was the presence of active or resorbed flecks. In our study, 50 patients (71%) had active retinal flecks in the macula and/or midperipheral retina of 1 or both eyes. In 7 of these 50 patients, flecks were only detected on AF imaging; in 2 (6.2%), AF identified macular atrophy that was not detected clinically (n = 11).

In the majority of patients (n = 38, 54.3%), active macular flecks were present, as identified clinically (n = 36), on AF imaging (n = 2), or both. The second most common clinical finding at the macula was atrophy, which was detected in over one-third (n = 26, 37.1%) of patients. Macular pigment mottling and bull’s-eye maculopathy were present in approximately one-quarter of cases (28.6% and 24.3%, respectively). There were no fundus abnormalities in the midperipheral and peripheral retina in 52 cases (74.3%). The most common sign in the retinal midperiphery was active flecks, present in 12 (17.1%) patients.

Findings on Fundus Autofluorescence Imaging

AF was the imaging technology most frequently used to aid in the diagnosis of STGD (Table 3). AF imaging was obtained in 32 patients (45.7%); an abnormal AF signal was found in all cases. In the majority of patients (n = 25, 78.2%), foci of increased or reduced AF signal (representing active and resolved flecks, respectively) were detected on AF imaging. A homogeneous background of fundus AF was observed in the midperipheral retina in three-quarters of patients (n = 24, 75.0%). Macular atrophy (central area of reduced AF signal) was present in 17 (53.1%). In 7 of the 32 who underwent AF (21.9%), flecks not visible on clinical examination were identified on AF; in 2 (6.2%), AF identified macular atrophy that was not detected clinically.

Table 3. Retinal Imaging Results

<table>
<thead>
<tr>
<th>Feature</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macula</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Reduced signal (atrophy)</td>
<td>17 (53.1)</td>
</tr>
<tr>
<td>Foci of increased signal</td>
<td>18 (56.3)</td>
</tr>
<tr>
<td>Foci of reduced signal</td>
<td>7 (21.9)</td>
</tr>
<tr>
<td>Midperipheral/peripheral retina</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>24 (75.0)</td>
</tr>
<tr>
<td>Reduced signal (atrophy)</td>
<td>3 (9.4)</td>
</tr>
<tr>
<td>Foci of increased signal</td>
<td>4 (12.5)</td>
</tr>
<tr>
<td>Foci of reduced signal</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Fundus fluorescein angiogram</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>1 (7.1)</td>
</tr>
<tr>
<td>Dark choroid</td>
<td>12 (18.5)</td>
</tr>
<tr>
<td>Window defect (atrophy)</td>
<td>5 (7.1)</td>
</tr>
</tbody>
</table>

*Fundus autofluorescence features were reported in 32 of 70 patients.
†Fundus fluorescein angiography features were reported in 14 of 70 patients.

Table 4. Family History of Patients with No Retinal Flecks on Examination and on Fundus Autofluorescence Imaging

<table>
<thead>
<tr>
<th>Patient Number</th>
<th>Positive Family History of STGD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2 sisters</td>
</tr>
<tr>
<td>2</td>
<td>Father</td>
</tr>
<tr>
<td>3</td>
<td>Father</td>
</tr>
<tr>
<td>4</td>
<td>1 brother</td>
</tr>
<tr>
<td>5</td>
<td>1 sister, 1 maternal uncle</td>
</tr>
<tr>
<td>6</td>
<td>1 paternal grandmother</td>
</tr>
<tr>
<td>7</td>
<td>1 brother</td>
</tr>
</tbody>
</table>

STGD = Stargardt disease.
Findings on Fundus Fluorescein Angiography

FFA was infrequently used in the evaluation of patients with STGD (n = 14, 20.0%) and revealed a dark choroid in most cases (n = 12, 85.7%).

Findings on Electrophysiology

Electrophysiology testing was undertaken in 50 patients (71.4%), including FFERG and PERG. In 45 of these 50 patients (90%), reduced macular function with normal FFERG (group 1 STGD) was found in most cases (n = 51, 73.3%), followed by reduced macular and peripheral cone function (group 2, n = 11, 15.6%) and reduced macular and peripheral rod and cone function (group 3, n = 8, 11.1%). In 5 patients (10%) electrophysiology testing was reported to be within normal limits. In these 5 patients, the diagnosis of STGD was based on the presence of flecks clinically (n = 3), dark choroid on FFA (n = 2), and ABCA4 mutations (n = 1, 2 disease-causing alleles identified).

Genetic Testing

Ten patients underwent genetic testing; in 9, ABCA4 mutations were identified in 1 (n = 4) or 2 (n = 5) alleles. Details of the allelic mutations found were given in 5 patients; these included c.4134C>T and c.5882G>A, p.Ala1038VAL and p.His1406.Tyr, p.C1490Y@c4469G, p.His1406.Tyr, p.C1490Y@c4469G, and p.L1580S:c.439T. The distribution of electrophysiology groups in the current study is very similar to that previously reported,8 with group 1 (macular dysfunction alone) being the most common and group 3 the least frequent (73% and 11% of patients in the current study with group 1 and group 3 STGD, respectively, compared with 68% and 17% of patients with group 1 and group 3 in our previous study).8 The pattern of functional loss as determined by FFERG and PERG has implications regarding disease prognosis and hence it is essential for the counseling of patients with STGD.8,14 Furthermore, the presence of a flat PERG is very characteristic of patients with STGD and can be a very helpful feature, if present, to establish the differential diagnosis between STGD and pattern dystrophy simulating STGD-FFM.8,15 In the latter, a normal or nearly normal PERG can be identified.16 The other main feature that allows this differentiation (and differentiating between ABCA4 and Peripherin/RDS [PRPH2] disease) is the presence of a relative peripapillary sparing in STGD,17 not observed in patients with pattern dystrophy. Interestingly, in a small proportion of patients (n = 5) with STGD presented herein, a normal PERG was reported; 1 of these had confirmed mutations in both alleles of ABCA4. Thus, it appears that a normal PERG can be present in a few patients with STGD and, thus, this feature should not rule out the diagnosis of this inherited retinal dystrophy. In patients with severe group 3 disease, the differentiation between STGD and retinitis pigmentosa may be challenging; in both, diffuse retinal abnormalities on slit-lamp biomicroscopy and widespread functional loss (reduced rod and cone function) in electrophysiology testing may be present. Under these circumstances, conventional AF (488 nm excitation) and near-infrared AF (787 nm excitation), as well as the PERG, may be useful disclosing a preserved central island of AF (in conventional or near-infrared AF) and residual macula, in a proportion, midperipheral/peripheral anatomic and functional abnormalities are detected and, thus, it would be more appropriate to classify STGD as an “inherited retinal disease” instead of an “inherited macular disease.”

The baseline characteristics identified in incident cases of STGD in this study are overall in agreement with previously published studies. Thus, approximately one-third of patients presented with a vision of 0.30 logMAR (Snellen equivalent 20/40) or better, consistent with published literature.8,11–13 In the latter, 18.6% (13/70) with a visual acuity of 1.0 (20/200 Snellen equivalent) or worse in the better-seeing eye. Retinal flecks and macular atrophy are the main clinical features of STGD.1 Herein, 50 patients (71.4%) had retinal flecks; in the vast majority macular and/or midperipheral/peripheral retinal flecks were evident on slit-lamp biomicroscopy (n = 43). However, in some patients (n = 7), flecks were not apparent clinically but were identified on AF imaging. This highlights the importance of this imaging technology to aid the diagnosis of STGD. It is well known, however, as Star-gardt pointed out in his original description of the disease, that flecks are not always present at the outset but can develop in time.1

The distribution of electrophysiology groups in the current study is very similar to that previously reported,8 with group 1 (macular dysfunction alone) being the most common and group 3 the least frequent (73% and 11% of patients in the current study with group 1 and group 3 STGD, respectively, compared with 68% and 17% of patients with group 1 and group 3 in our previous study).8 The pattern of functional loss as determined by FFERG and PERG has implications regarding disease prognosis and hence it is essential for the counseling of patients with STGD.8,14 Furthermore, the presence of a flat PERG is very characteristic of patients with STGD and can be a very helpful feature, if present, to establish the differential diagnosis between STGD and pattern dystrophy simulating STGD-FFM.8,15 In the latter, a normal or nearly normal PERG can be identified.16 The other main feature that allows this differentiation (and differentiating between ABCA4 and Peripherin/RDS [PRPH2] disease) is the presence of a relative peripapillary sparing in STGD,17 not observed in patients with pattern dystrophy.

Discussion

This study represents what we believe to be the first nationwide prospective study aimed at determining the incidence and presenting characteristics of patients with STGD. Herein, the incidence of STGD was found to be 0.127 per 100 000 population per year, which is much lower than the rough estimate of 1 in 10 000 hitherto repeatedly quoted in the literature. There is a possibility that the incidence of STGD may be even higher than that reported herein, because of incomplete ascertainment, which is a known limitation of surveillance studies. Nonetheless, it would be unlikely that the incidence would deviate markedly from that estimated herein. It was not possible to know whether reported cases for which baseline data were not collected (n = 11, 13.6%) (i.e., those cases reported but from which questionnaires were not returned) were indeed cases of STGD. Nonetheless, every effort was made to retrieve all cases seen during the period of the study, not only through active, prospective surveillance by the BOSU but also through contacting the largest reference centers in the UK for inherited retinal diseases. Furthermore, patients initially reported who required additional testing to confirm the diagnosis of STGD were captured in the study by data collected through the 6-month questionnaire.

STGD is often considered a form of juvenile macular dystrophy.4,9,10 Based on current findings, it seems that most patients present in early adulthood. As reported previously, however, the disease can have an onset at any stage of life, with the oldest patient reported being in the seventh decade of life.8 Furthermore, it is clear that, although in most patients the disease is confined to the
PERG in patients with retinitis pigmentosa and marked reduced AF (in conventional AF and near-infrared AF) and a flat PERG in STGD.18,19 The current study suggests that fundus AF imaging and PERG are widely used in the UK to aid in the diagnosis of STGD. It also suggests that fundus AF imaging has superseded the more invasive FFA. During the period of the study, genetic testing was rarely carried out. It is possible that the scarce use of genetic testing related to the fact that, unlike in other monogenic retinal dystrophies, results of ABAG4 testing are not always easily interpretable. ABAG4 mutations are not exclusive of patients with STGD but can be identified in other inherited retinal dystrophies, such as bull’s-eye maculopathy,20 cone-rod dystrophy,21 and retinitis pigmentosa.22 Furthermore, sequencing of the complete coding sequence in patients with clinical features of STGD often fails to reveal 1 or both ABAG4 mutations.5,23–25

Despite its possible limitations, this study provides a more accurate estimate of the incidence of STGD and a good indication of the presenting characteristics of these patients. The insight gained is valuable to inform the design of therapeutic trials for this condition.

Acknowledgments. The authors thank the British Ophthalmological Surveillance Unit (BOSU) for the support received, as well as Mr Barnaby Foot, research coordinator for BOSU, for his help and advice on this project. The authors thank the following ophthalmologists who assisted with data collection for this study: N. Acharaya, S. Anwar, V. Bansal, P.N. Bishop, D. Byles, J.S. Chawla, A. Churchill, M. Clarke, B. Dhillon, M. Ekstein, S. George, J. Gillian, J.T. Gillow, A. Lotery, M. Lloyd, A. Lotery, M. McKibbin, R. MacLaren, G. Menon, A.T. Moore, A. Mulvihill, Y. Osoba, R. Pilling, H. Porooshani, A. Raghu Ram, T. Rimmer, J. Russell-Eggitt, M. Sarhan, R. Savides, S. Shafquat, A. Smith, A. Tekriwal, P. Tesh, P. Watts.

References

Footnotes and Financial Disclosures

Originally received: February 7, 2017.
Final revision: February 27, 2017.
Accepted: March 3, 2017.
Available online:  ■ ■ ■ ■  Manuscript no. ORET_2017_36.
1 Sheffield Teaching Hospitals NHS Trust, Sheffield, England, United Kingdom.
2 Moorfields Eye Hospital, London, England, United Kingdom.
4 Oxford University Hospitals, Oxford, England, United Kingdom.
5 Medical Statistics Team, University of Aberdeen, Aberdeen, Scotland, United Kingdom.
6 Queens University, Belfast, Northern Ireland, United Kingdom.

Financial Disclosure(s):
Supported by the Fighting for Sight Aberdeen (Registered Charity SC033004). The funding organization had no role in the design or conduct of this research.
Conflict of interest: No conflicting relationship exists for any author.

Author Contributions:
Research design: Spiteri Cornish, Lois
Data analysis and/or interpretation: Spiteri Cornish, Ho, Downes, Scott, Lois
Data acquisition and/or research execution: Spiteri Cornish, Ho, Downes, Scott, Bainbridge, Lois
Manuscript preparation: Spiteri Cornish, Lois

Abbreviations and Acronyms:
AF = autofluorescence; BOSU = British Ophthalmological Surveillance Unit; FFA = fundus fluorescein angiography; FFERG = full-field electroretinography; FFM = fundus flavimaculatus; logMAR = logarithm of the minimum angle of resolution; PERG = pattern electroretinography; PR = photoreceptor; RPE = retinal pigment epithelium; STGD = Stargardt disease; UK = United Kingdom.

Correspondence:
Noemi Lois, MD, PhD, Wellcome-Wolfson institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, UK. E-mail: n.lois@qub.ac.uk.